ATE239756T1 - Humaner monoklonaler antikörper gegen hepatitis b virus oberflächen antigen (hbvsag) - Google Patents

Humaner monoklonaler antikörper gegen hepatitis b virus oberflächen antigen (hbvsag)

Info

Publication number
ATE239756T1
ATE239756T1 AT97925252T AT97925252T ATE239756T1 AT E239756 T1 ATE239756 T1 AT E239756T1 AT 97925252 T AT97925252 T AT 97925252T AT 97925252 T AT97925252 T AT 97925252T AT E239756 T1 ATE239756 T1 AT E239756T1
Authority
AT
Austria
Prior art keywords
hbvsag
antibodies
surface antigen
virus surface
human monoclonal
Prior art date
Application number
AT97925252T
Other languages
English (en)
Inventor
Shlomo Dagan
Original Assignee
Xtl Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xtl Biopharmaceuticals Ltd filed Critical Xtl Biopharmaceuticals Ltd
Application granted granted Critical
Publication of ATE239756T1 publication Critical patent/ATE239756T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97925252T 1996-06-11 1997-06-10 Humaner monoklonaler antikörper gegen hepatitis b virus oberflächen antigen (hbvsag) ATE239756T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11862696A IL118626A0 (en) 1996-06-11 1996-06-11 Anti HBV antibody
PCT/IL1997/000183 WO1997047653A1 (en) 1996-06-11 1997-06-10 Human monoclonal antibody against hepatitis b virus surface antigen (hbvsag)

Publications (1)

Publication Number Publication Date
ATE239756T1 true ATE239756T1 (de) 2003-05-15

Family

ID=11068956

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97925252T ATE239756T1 (de) 1996-06-11 1997-06-10 Humaner monoklonaler antikörper gegen hepatitis b virus oberflächen antigen (hbvsag)

Country Status (12)

Country Link
US (2) US6146629A (de)
EP (1) EP0853633B1 (de)
JP (1) JP3574664B2 (de)
AT (1) ATE239756T1 (de)
AU (1) AU3045497A (de)
CA (1) CA2227548C (de)
DE (1) DE69721713T2 (de)
DK (1) DK0853633T3 (de)
ES (1) ES2197345T3 (de)
IL (3) IL118626A0 (de)
PT (1) PT853633E (de)
WO (1) WO1997047653A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180284A1 (en) * 1998-11-05 2003-09-25 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
DE19939653A1 (de) * 1999-08-13 2001-02-22 Thomas Huenig Verwendung CD28 spezifischer monoklonaler Antikörper zur Herstellung einer pharmazeutischen Zusammensetzung
KR100419555B1 (ko) * 2000-05-29 2004-02-19 주식회사유한양행 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자
NZ527302A (en) 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
CA2441228A1 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
JP2004536835A (ja) * 2001-07-09 2004-12-09 アフトン コーポレーション 肝臓、肺および食道の癌性ならびに前癌性状態の治療および防止
SG153666A1 (en) * 2001-10-04 2009-07-29 Yeda Res & Dev Treatment of hepatitis b virus infection with human monoclonal antibodies
CA2462427A1 (en) * 2001-10-04 2003-04-10 Xtl Biopharmaceuticals Ltd Treatment of hepatitis b virus infection with human monoclonal antibodies
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
KR100467706B1 (ko) * 2002-01-15 2005-01-24 주식회사 녹십자홀딩스 B형 간염 바이러스의 표면 항원에 대한 인간항체
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
KR20050109489A (ko) * 2003-02-13 2005-11-21 화이자 프로덕츠 인크. 항-인슐린양 성장인자 i 수용체 항체의 용도
CN1835975B (zh) * 2003-08-13 2012-11-21 辉瑞产品公司 经修饰的人类igf-1r抗体
CN101014365B (zh) * 2004-07-16 2011-04-13 辉瑞产品公司 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
WO2006085141A2 (en) * 2004-08-13 2006-08-17 Migenix Inc. Compositions and methods for treating or preventing hepadnaviridae infection
EP2567974A3 (de) 2004-09-22 2013-05-22 Cancer Advances, Inc., Monoklonale Antikörper gegen Progastrin
CA2594922A1 (en) * 2005-01-14 2006-07-20 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize hepatitis b virus
ES2407468T3 (es) 2005-04-18 2013-06-12 Yeda Research And Development Company Limited Formulaciones de anticuerpos anti-hepatitis B (HBV) estabilizadas
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US20100150942A1 (en) * 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
CA2884388A1 (en) 2012-09-27 2014-04-03 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing hepatitis b viruses and uses thereof
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
IL271427B2 (en) 2017-06-15 2025-08-01 Cancer Advances Inc Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
CN119490583A (zh) 2018-05-31 2025-02-21 诺华股份有限公司 乙型肝炎抗体
TWI868379B (zh) * 2020-07-09 2025-01-01 大陸商北京凱因科技股份有限公司 結合b型肝炎病毒表面抗原的抗體及其應用
CN114671947B (zh) * 2022-02-28 2024-04-09 中国科学院生物物理研究所 乙肝病毒不同亚型表面s蛋白高亲和力纳米抗体及其应用
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5931799A (ja) * 1982-08-16 1984-02-20 Science & Tech Agency B型肝炎ウイルス遺伝子を組込んだ組換えプラスミド
US4714613A (en) * 1982-09-30 1987-12-22 The Albert Einstein College Of Medicine Of Yeshiva University Method of suppressing cell growth by immunotherapy
US4624918A (en) * 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
JPS61104796A (ja) * 1984-10-26 1986-05-23 Chemo Sero Therapeut Res Inst モノクロ−ナル抗体の製造方法
JPS61179483A (ja) * 1985-02-04 1986-08-12 Sharp Corp 感光体疲労防止装置
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US5565354A (en) * 1986-09-05 1996-10-15 Sandoz Ltd. Production of human monoclonal antibodies specific for hepatitis B surface antigen
EP0468119A1 (de) * 1990-07-24 1992-01-29 Merrell Dow Pharmaceuticals Inc. Neue Carbocyclische Analoge einiger Nukleoside
GB9202796D0 (en) 1992-02-11 1992-03-25 Wellcome Found Antiviral antibody
AU684455B2 (en) * 1992-11-06 1997-12-18 Sandoz Ltd. Production of human monoclonal antibodies active against hepatitis B surface antigen
EP0698042A1 (de) * 1993-05-10 1996-02-28 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis Antikoerperzusammensetzung gegen hepatitis-b-virus oberflaechenantigen
GB9608626D0 (en) 1996-04-25 1996-07-03 Univ College Of London Hepatitis b monoclonal antibodies
IL118625A0 (en) * 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibodies

Also Published As

Publication number Publication date
AU3045497A (en) 1998-01-07
DK0853633T3 (da) 2003-08-04
CA2227548C (en) 2004-07-20
IL118626A0 (en) 1996-10-16
USRE39586E1 (en) 2007-04-24
IL123025A (en) 2006-09-05
CA2227548A1 (en) 1997-12-18
EP0853633A1 (de) 1998-07-22
ES2197345T3 (es) 2004-01-01
JP2000506741A (ja) 2000-06-06
EP0853633B1 (de) 2003-05-07
DE69721713D1 (de) 2003-06-12
PT853633E (pt) 2003-09-30
WO1997047653A1 (en) 1997-12-18
US6146629A (en) 2000-11-14
JP3574664B2 (ja) 2004-10-06
DE69721713T2 (de) 2004-03-11
IL123025A0 (en) 1998-09-24

Similar Documents

Publication Publication Date Title
DE69721713D1 (de) Humaner monoklonaler antikörper gegen hepatitis b virus oberflächen antigen (hbvsag)
ATE256148T1 (de) Menschliche monoklonale antikörper gegen das hepatitis b oberflächenantigen
ATE185606T1 (de) Monoklonale antikörper gegen putative hcv-e2/ns1- proteine und verfahren zu ihrer verwendung
DK0773228T3 (da) Fremgangsmåde til fremstilling af monoklonale human-antistoffer og deres anvendelse
ATE13692T1 (de) Hybridzellinie zur herstellung komplementfixierender monoklonaler antikoerper gegen menschliche suppressor-t-zellen; antikoerper und verfahren zu seiner herstellung; diagnostische und therapeutische verwendungen und diesen antikoerper enthaltende pharmazeutische zusammensetzungen.
KR890701771A (ko) Hiv 항원에 특이적인 단일 클론 항체
UA50708C2 (uk) Моноклональне антитіло, яке має здатність розпізнавати антиген, який викликає апоптоз мієлоїдних клітин, фрагмент f(ab)2 моноклонального антитіла, гібридома ferm bp-4382
ATE122237T1 (de) Hiv-1 neutralisierende monoklonale antikörper.
FI931393A0 (fi) Peptider foer anvaendning vid vaccinering och induktion av neutraliserande motkroppar mot humant immunbristvirus
DE69932812D1 (de) Epitope in der viralen hüllproteine und spezifische antikörper gegen diese epitope: verwendung für die detektion von hcv viralantigene im empfängergewebe
DE3584872D1 (de) Verfahren zur herstellung von monoklonalen antikoerpern gegen hbsag.
DE60141832D1 (de) Humaner monoklonaler antikörper gegen das hepatitis c virus e2 glykoprotein
FR2560212B1 (fr) Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
DE69224134D1 (de) Monoklonale Antikörper gegen Hepatitis-C-Virus
ATE167522T1 (de) Monoklonale antikörper gegen mögliche hcv- hüllregionen und methoden diese zu benutzen
DE69941051D1 (de) Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisier
CA2254931A1 (en) Human monoclonal antibodies to the hepatitis b surface antigen
Sallberg et al. The Antigen/Antibody Specificity Exchanger: A New Peptide-Based Tool for Re-directing Antibodies of Other Specificities to Recognize the V3 Domain of HIV-1 GP120
DE69227776D1 (de) Monoklonale antikörper gegen mutmassliche hepatitis c-virus ns5-proteine und ihre anwendungsmethoden
FI924278A0 (fi) Bcrf1 antagonister foer skoetsel av epstein-barr-virusinfektioner.
EP0089771A3 (de) ATCC HB 8116 und sein monoklonaler anti-h-y Antikörper, hyklonalan
SU1692146A1 (ru) Штамм гибридных культивируемых клеток животных mus musculus l. - продуцент моноклональных антител к 146 s-компоненту вируса ящура o

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0853633

Country of ref document: EP

EEIH Change in the person of patent owner